IP Library Granted Patent US 12,440,530
Granted Patent B2
US 12,440,530 · App. 18/376,038 · Granted Oct 14, 2025

Skin solution with solubilized bakuchiol

Inventors: Felipe Jimenez (Rialto, CA); Lyndon Garcines (Fountain Valley, CA); Susan Goldsberry (Huntington Beach, CA); Senad Ibrulj (Santa Ana, CA)
Assignee: ENVY MEDICAL, INC.
A61K36/487A61K8/34A61K8/347A61K8/9789A61K9/0014A61K9/06A61K31/045A61K31/05A61K31/07A61K31/19A61K31/203A61K31/327A61K31/4436A61K31/60A61K31/7048A61K31/7056A61K47/10A61K47/12A61K47/183A61K47/22A61K47/26A61K47/38A61Q19/00A61K2236/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,530
App. No.
18/376,038
Granted
Oct 14, 2025
Kind
B2
Abstract

A composition for the treatment of acne includes hydrolyzed Psoralea corylifolia , containing a component bakuchiol, is solubilized in a water-based solution. The composition is for topical application to the skin. In various implementations, the composition is a water-based acne gel or a water-based cleanser. In a specific implementation, a composition includes Bakutrol™, which includes bakuchiol, and bisabolol. The composition can include a polysorbate surfactant. In implementations, these ingredients are combined with other active ingredients, including for example, salicylic acid, benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these. A process of preparation of the composition allows for the stabilization of Bakutrol in solution.

Claims (27)

1. A topical composition comprising:

(i) about 0.05 wt % to about 2.00 wt % of bakuchiol;

(ii) about 0.05 wt % to about 2.00 wt % of bisabolol;

(iii) about 0.5 wt % to about 2.00 wt % of salicylic acid;

(iv) about 4.8 wt % to about 22 wt % of decyl glucoside;

(v) one or more skin conditioners;

(vi) Perilla ocymoides leaf extract;

(vii) Olea europaea extract; and

(viii) about 70 wt % to about 99 wt % water.

2. The topical composition of claim 1 further comprising one or more surfactants selected from the group consisting of polysorbate, cocamidopropyl betaine, caprylyl glycol, PPG-2 isoceteth-20-acetate and combinations thereof.

3. The topical composition of claim 1 wherein the one or more skin conditioners are selected from the group consisting of aloe, Sapindus mukurossi extract, dipotassium glycyrrhizate and combinations thereof.

4. The topical composition of claim 1 further comprising a viscosity controlling agent.

5. A method of treating acne comprising applying the composition defined in claim 1 to an area of a subject's skin in need of such treatment.

6. The topical composition of claim 1 wherein the one or more skin conditioners comprises about 0.01 wt % to about 5.0 wt % of Sapindus mukurossi extract.

7. The topical composition of claim 1 wherein the one or more skin conditioners comprises about 0.01 wt % to about 5.0 wt % of dipotassium glycyrrhizate.

8. A topical composition comprising:

(i) about 0.05 wt % to about 2.00 wt % of bakuchiol;

(ii) about 0.05 wt % to about 2.00 wt % of bisabolol;

(iii) about 0.5 wt % to about 2.00 wt % of salicylic acid;

(iv) about 4.8 wt % to about 22 wt % of decyl glucoside;

(v) about 0.01 wt % to about 5.0 wt % of Sapindus mukurossi extract;

(vi) about 0.01 wt % to about 5.0 wt % of dipotassium glycyrrhizate;

(vii) Perilla ocymoides leaf extract;

(viii) Olea europaea extract;

(ix) a viscosity controlling agent; and

(x) about 70 wt % to about 99 wt % water.

9. A method of treating acne comprising applying the composition defined in claim 8 to an area of a subject's skin in need of such treatment.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2025
From: GARCINES, LYNDON; GOLDSBERRY, SUSAN; IBRULJ, SENAD
To: ENVY MEDICAL, INC.
Reel/Frame 072286/0454 →
Continuity (5)
Continuation 15257318 · Sep 6, 2016
Continuation 14692718 · Apr 21, 2015
Continuation In Part 13783066 · Mar 1, 2013
Provisional Application 61982229 · Apr 21, 2014
Related Publication 20240139269A1 · May 2, 2024
References Cited (87)
US 4067967A · Prince · 1978 [cited by applicant]
US 4096240A · Mathur · 1978 [cited by applicant]
US 4126681A · Reller · 1978 [cited by applicant]
US 4318907A · Klingman et al. · 1982 [cited by applicant]
US 4369180A · Mihalovits · 1983 [cited by applicant]
US 4388301A · Klein · 1983 [cited by applicant]
US 5204105A · Mausner · 1993 [cited by applicant]
US 5569651A · Garrison et al. · 1996 [cited by applicant]
US 5891451A · Guerrero et al. · 1999 [cited by applicant]
US 6099849A · Mansouri · 2000 [cited by applicant]
US 6221372B1 · Golz-Berner et al. · 2001 [cited by applicant]
US 6589514B2 · Jensen et al. · 2003 [cited by applicant]
US 7138129B2 · Cho et al. · 2006 [cited by applicant]
US 7402669B2 · Loiseau et al. · 2008 [cited by applicant]
US 8017581B1 · Martinez et al. · 2011 [cited by applicant]
US 8163706B2 · Loiseau et al. · 2012 [cited by applicant]
US 8652535B2 · Jia et al. · 2014 [cited by applicant]
US 9295723B2 · Garcines et al. · 2016 [cited by applicant]
US 9433587B2 · Jimenez et al. · 2016 [cited by applicant]
US 10201509B2 · Garcines et al. · 2019 [cited by applicant]
US 20020187168A1 · Jensen et al. · 2002 [cited by applicant]
US 20040156873A1 · Gupta · 2004 [cited by applicant]
US 20060110415A1 · Gupta · 2006 [cited by applicant]
US 20060210612A1 · Simon · 2006 [cited by examiner]
US 20060251749A1 · Jia et al. · 2006 [cited by applicant]
US 20070224229A1 · Gibbons et al. · 2007 [cited by applicant]
US 20080069898A1 · Smith et al. · 2008 [cited by applicant]
US 20080102137A1 · Guffey · 2008 [cited by applicant]
US 20080124312A1 · Lovaas · 2008 [cited by applicant]
US 20090036545A1 · Chaudhuri · 2009 [cited by examiner]
US 20090117061A1 · Gross · 2009 [cited by applicant]
US 20090137534A1 · Chaudhuri · 2009 [cited by applicant]
US 20100040696A1 · Sente et al. · 2010 [cited by applicant]
US 20100093599A1 · Wu · 2010 [cited by examiner]
US 20100247563A1 · Hines et al. · 2010 [cited by applicant]
US 20100260695A1 · Burke-Colvin · 2010 [cited by examiner]
US 20100323042A1 · Collins et al. · 2010 [cited by applicant]
US 20110151032A1 · Levine et al. · 2011 [cited by applicant]
US 20120058167A1 · Widgerow · 2012 [cited by applicant]
US 20120093755A1 · Humphreys et al. · 2012 [cited by applicant]
US 20120093953A1 · Faller et al. · 2012 [cited by applicant]
US 20120114719A1 · Morariu · 2012 [cited by applicant]
US 20120201769A1 · Hong et al. · 2012 [cited by applicant]
US 20120271251A1 · Webb · 2012 [cited by applicant]
US 20130065843A1 · Rupasinghe et al. · 2013 [cited by applicant]
US 20140038875A1 · McCarthy et al. · 2014 [cited by applicant]
US 20140107046A1 · Pan et al. · 2014 [cited by applicant]
US 20140249116A1 · Garcines et al. · 2014 [cited by applicant]
US 20140349902A1 · Allef et al. · 2014 [cited by applicant]
US 20150238440A1 · Jimenez et al. · 2015 [cited by applicant]
US 20160206573A1 · Garcines et al. · 2016 [cited by applicant]
US 20160331676A1 · Laville et al. · 2016 [cited by applicant]
US 20170281503A1 · Pan et al. · 2017 [cited by applicant]
US 20180064777A1 · Jimenez et al. · 2018 [cited by applicant]
US 20180116936A1 · Pan et al. · 2018 [cited by applicant]
US 20180116950A1 · Pan et al. · 2018 [cited by applicant]
US 20180133138A1 · Tarres et al. · 2018 [cited by applicant]
US 20180256482A1 · Jordan et al. · 2018 [cited by applicant]
US 20180369110A1 · Hakozaki et al. · 2018 [cited by applicant]
US 20190380945A1 · Hakozaki et al. · 2019 [cited by applicant]
US 20200009123A1 · Hakozaki et al. · 2020 [cited by applicant]
US 20210196590A1 · James et al. · 2021 [cited by applicant]
US 20210353699A1 · Afornali · 2021 [cited by applicant]
US 20210369588A1 · Zhang et al. · 2021 [cited by applicant]
CN 104095770 · 2014 [cited by applicant]
EP 2497481 · 2012 [cited by applicant]
WO 2004093832 · 2004 [cited by applicant]
WO 2006122160 · 2006 [cited by applicant]
WO 2008140673 · 2008 [cited by applicant]
WO 2008143761 · 2008 [cited by applicant]
WO 201216391 · 2012 [cited by applicant]
WO 2014132060 · 2014 [cited by applicant]
WO 2014134620 · 2014 [cited by applicant]
WO 2015164433 · 2015 [cited by applicant]
WO 2017069157 · 2017 [cited by applicant]
International Search Reoprt and Written Opinion, PCT Appliction PCT/US2015/026958, Aug. 5, 2015, 15 pages. [cited by applicant]
Chahuni, et al., “Bakuchiol in the Management of Acne-Affected Skin,” Cosmetics and Toiletries Magazine, 2011, vol. 126, No. 7, pp. 502-510. [cited by applicant]
International Search Report, PCT Application PCT/US2014/020017, Jun. 26, 2014, 3 pages. [cited by applicant]
Written Opinion, PCT Application PCT/US2014/020017, Jun. 26, 2014, 7 pages. [cited by applicant]
Sodhala, Sodhalanighantaub, Edn 1st 1978, pp. 4-8, Oriental Institute, Baroda, India. [cited by applicant]
Ziya Al-Din Abdullah Ibn Al_Baitar, Al-Jaam'e-li-Mufradaat-a;-Advia-wal-Aghzia, vol. IV (13th Century AD), 1874 AD, pp. 9-14, Matba Amra, Cairo, Egypt. [cited by applicant]
Mohammad Akmal Khan,Qaraabaadeen Azam wa Akmal, 1909 AD, pp. 15-18, Matba Siddiqi/Matba Mustafai, Delhi, India. [cited by applicant]
Acunutol™ Gel, Topical gel designed to support acute skin and acne conditions, Designs for Health [retrieved from on-line website:http://mkt.s.designsforhealth.com/Label_PDF/AcnutrolGel-Techsheet.pdf,last visit OCt. 19,… [cited by applicant]
Supplemental European Search Report for European Patent Application Publication No. 3134078, Oct. 26, 2017. [cited by applicant]
Argan & Retinol Night Cream Product Description, GNPD database record id 2323286, www.gnpd.com, Mar. 1, 2014. [cited by applicant]
Arbonne Intelligence Genius, http://www.arbonnemarketing.com, Sep. 1, 2013. [cited by applicant]
Therapeutics Update, Practical Dermatology, http://practicaldermatology.com/pdfs/pd0313_Therapeutics.pdf, Mar. 1, 2013 pp. 48-49. [cited by applicant]